On February 25, 2015, The U.S. Food and Drug Administration approved Avycaz (ceftazidime-avibactam) to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.Avycazis a fixed-combination drug containing ceftazidime and avibactam, a new beta-lactamase inhibitor.

See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm for more info.